SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC.
Saved in:
| Title: | SUNRAY-01 trial protocol: an innovative study design of olomorasib and pembrolizumab with or without chemotherapy in KRAS G12C NSCLC. |
|---|---|
| Authors: | Peters S; Oncology Department, Lausanne University and CHUV, Lausanne, Switzerland., Hochmair M; Department of Respiratory and Critical Care Medicine, Karl Landsteiner Institute for Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria., Arbour KC; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rodriguez LP; Medical Oncology Department, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, Spain., Reck M; Department of Thoracic Oncology, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany., Leal T; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA., R Lindsay C; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Shun L; Shangai Lung Cancer Centre, Shanghai Chest Hospital, School of Medicine, Shangai Jiaotong University, Shanghai, China., William WN; Grupo Oncoclínicas, São Paulo, Brazil., Spira AI; Virginia Cancer Specialists, Fairfax, VA, USA., Sabari JK; Perlmutter Cancer Centre, NYU Langone Health, New York, NY, USA., Henning Grønberg B; Department of Clinical and Molecular Medicine, NTNU, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway., Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan., Burns TF; Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Colombus, OH, USA., Girard N; Institut du Thorax Curie Montsouris, Institut Curie, Paris, France.; UVSQ, Paris Saclay University, Versailles, France., Capuzzo F; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Merced A; Eli Lilly and Company, Indianapolis, IN, USA., Fasnacht N; Eli Lilly and Company, Indianapolis, IN, USA., Visseren-Grul C; Eli Lilly and Company, Indianapolis, IN, USA., Negrao MV; Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2026 Apr; Vol. 22 (9), pp. 1073-1082. Date of Electronic Publication: 2026 Apr 06. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
